ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC - Get Free Report) insider Pratik S. Multani sold 8,850 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $8.28, for a total value of $73,278.00. Following the sale, the insider now directly owns 46,765 shares in the company, valued at $387,214.20. This represents a 15.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
ORIC Pharmaceuticals Stock Up 0.1 %
ORIC stock opened at $8.25 on Wednesday. The business has a 50 day moving average price of $9.35 and a 200 day moving average price of $9.37. The stock has a market cap of $582.18 million, a price-to-earnings ratio of -4.58 and a beta of 1.13. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $6.33 and a fifty-two week high of $16.65.
ORIC Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current year.
Analyst Upgrades and Downgrades
Most People Are Dead Wrong.
From Brownstone Research | Ad
Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence.
Everyone's talking about AI right now.
But see, I've been talking about it for years.
I call it my AI Retirement Playbook. I recommend you check it out now.
Several research firms recently commented on ORIC. Cantor Fitzgerald reissued an "overweight" rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Wedbush reissued an "outperform" rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. HC Wainwright restated a "buy" rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research note on Monday, November 4th. Wells Fargo & Company assumed coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They issued an "overweight" rating and a $20.00 price target for the company. Finally, Stifel Nicolaus started coverage on shares of ORIC Pharmaceuticals in a research report on Friday, September 6th. They issued a "buy" rating and a $20.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $18.29.
View Our Latest Stock Report on ORIC Pharmaceuticals
Hedge Funds Weigh In On ORIC Pharmaceuticals
Large investors have recently bought and sold shares of the stock. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of ORIC Pharmaceuticals during the second quarter worth about $724,000. Bank of New York Mellon Corp grew its stake in ORIC Pharmaceuticals by 62.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company's stock worth $1,318,000 after buying an additional 71,394 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in ORIC Pharmaceuticals by 162.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company's stock worth $36,000 after buying an additional 3,188 shares during the last quarter. Rhumbline Advisers increased its position in ORIC Pharmaceuticals by 53.7% during the second quarter. Rhumbline Advisers now owns 92,702 shares of the company's stock worth $655,000 after buying an additional 32,402 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in ORIC Pharmaceuticals by 8.3% in the second quarter. Victory Capital Management Inc. now owns 95,850 shares of the company's stock valued at $678,000 after buying an additional 7,310 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.
About ORIC Pharmaceuticals
(
Get Free Report)
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
